Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to make more people with cycstic fibrosis eligible for keftrio treatment; and what the timescale is for that work.

Kaftrio is available to National Health Service patients in line with its marketing authorisation through an interim access deal negotiated between NHS England and NHS Improvement and Vertex, the drug manufacturer. This deal will last for four years and means that eligible NHS patients are among the first in Europe to benefit from access to Kaftrio. The deal has been structured to allow patients access if the license is updated during the term of the agreement.